Sailun Property Performance Brief: Net profit attributable to parent company in 2025 is 51.7135 million yuan, a year-on-year increase of 16.76%

Sailun Biotech’s 2025 Performance Brief released on February 26 shows that during the reporting period, the company achieved operating revenue of 196 million yuan, a year-on-year increase of 0.66%; net profit attributable to shareholders of the listed company was 51.7135 million yuan, a year-on-year increase of 16.76%; basic earnings per share were 0.48 yuan. The net profit growth this period is mainly due to the company’s recognition of investment losses in the joint venture Shanghai Sailun Biotech Co., Ltd., and the full impairment provision for long-term equity investments, as well as the combined effects of a decrease in non-recurring gains and losses and a reduction in R&D expenses compared to the same period last year.